O6-benzylguanine
O6-benzylguanine is a pharmaceutical drug with 29 clinical trials. Currently 1 active trials ongoing. Historical success rate of 76.0%.
Success Metrics
Based on 19 completed trials
Phase Distribution
Phase Distribution
17
Early Stage
9
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
67.9%
19 of 28 finished
32.1%
9 ended early
1
trials recruiting
29
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
BG & TMZ Therapy of Glioblastoma Multiforme
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Clinical Trials (29)
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
BG & TMZ Therapy of Glioblastoma Multiforme
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 29